1 Risk of COVID-19 breakthrough infection and hospitalization in individuals with 2 comorbidities

- 3 Peter D Smits, PhD¹; Samuel Gratzl, PhD¹, PhD; Michael Simonov, MD^{1,2;} Senthil K
- 4 Nachimuthu, MD, PhD¹; Brianna M Goodwin, MS¹; Michael D Wang, MD¹; Benjamin M
- 5 Althouse, PhD, ScM^{1,3,4}; Nicholas L Stucky, MD, PhD^{1,‡}
- 6
- 7 ¹ Truveta Incorporated, Bellevue, WA
- 8 ² Yale School of Medicine, New Haven, CT
- 9 ³ Information School, University of Washington, Seattle, WA
- ⁴ Department of Biology, New Mexico State University, Las Cruces, NM
- 11
- 12 ‡ To whom correspondence should be addressed
- 13 Dr Nicholas L Stucky
- 14 Truveta, Inc
- 15 1745 114th Ave SE, Bellevue, WA 98004
- 16 Email: <u>nicholass@truveta.com</u>
- 17
- 18 Keywords: COVID-19; breakthrough infection; comorbid conditions; COVID-19 hospitalization
- 19

21

25

26

- 20 Highlights:
 - COVID-19 infection has greater severity in those with comorbidities.
- Here we investigate the risk of breakthrough infections and hospitalizations in fully-vaccinated individuals with and without comorbidities.
 We find increased rates of breakthrough infections with all comorbidities, with CKD
 - We find increased rates of breakthrough infections with all comorbidities, with CKD having the greatest risk.
 - Individuals with chronic lung disease had the highest rate of breakthrough infection, but the lowest subsequent risk of hospitalization.
 - Individuals with comorbidities should remain vigilant against infection even if vaccinated.
- 28 29
- 30 Conflict of Interest: All authors are employees of Truveta, Inc.
- 31
- 32 Acknowledgements: The authors thank Mackenzie Bogiages and Ari Robicsek for helpful
- comments on the manuscript and statistical analyses, and Ian Davies for help with establishing
 the code repository. This study was funded by Truveta, Inc.
- 35
- 36 Ethical Approval: This study was reviewed by the Providence St. Joseph Health Institutional
- 37 Review Board (IRB) as STUDY2022000212 and determined Not Human Research. 45 CFR
- 38 46.102(e)(1).
- 39

40 Abstract

41 Background

42 Studies have shown that those with certain high-risk comorbidities such as diabetes, chronic

43 kidney disease (CKD), chronic lung disease, or those with immunocompromising conditions

44 have increased risk of hospitalization from COVID-19. Here we estimate the elevated risks of

45 breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities.

- 46
- 47 Methods

48 Using a population of fully-vaccinated patients in the de-identified Truveta Platform of electronic 49 health records from January 1, 2019, to January 10, 2022, we used logistic regression to

50 estimate risk of 1) a patient experiencing a breakthrough COVID-19 infection after being fully

51 vaccinated, and 2) rate of hospitalization in those experiencing breakthrough infection. Potential

52 confounding was adjusted with inverse probability weighting for each comorbidity by age, race,

53 ethnicity, and sex. We present ORs and percentages of breakthrough infections by comorbidity status.

54

55

56 Results

57 Of 3,424,965 fully vaccinated patients, 2.79%, 2.63%, 2.38%, 1.83% with CKD, chronic lung

58 disease, diabetes, and those in an immunocompromised state experienced breakthrough

59 infection, respectively, compared to 1.95% in the overall population. All cormorbidities were

60 associated with significantly increased odds of breakthrough infections and subsequent

61 hospitalizations. Breakthrough infection hospitalizations in populations with comorbidities

62 ranged from 26.43% for CKD to 10.23% for chronic lung disease, with corresponding ORs of

63 2.22 (95% CI: 1.88 - 2.63) and 1.37 (95% CI: 1.21 - 1.55), respectively.

- 64
- 65 Conclusions

66 Fully-vaccinated individuals with certain comorbidities experienced increased risk of

67 breakthrough COVID-19 infection and subsequent hospitalizations compared to the general

68 population. Individuals with comorbidities should remain vigilant against infection even if

- 69 vaccinated.
- 70
- 71

72 Introduction

- 73 Reports of declining vaccine effectiveness against COVID-19 after the primary series have
- 74 driven discussion about booster vaccinations (1,2). On September 24, 2021, Pfizer booster
- vaccinations were approved based on data showing waning vaccine immunity against infection.
- 76 On October 21, 2021, the CDC expanded its recommendation to include boosters for Moderna
- and Janssen vaccines. These decisions were based largely on declines in vaccine effectiveness
- in the elderly population in both U.S. and Israeli populations (3). The CDC recommended
- 50 booster vaccinations for people aged 50 or over with high-risk medical conditions while stating
- 80 that people aged 18-49 with high-risk medical conditions may receive the vaccine based on
- 81 limited unpublished CDC data (4). Nevertheless, only limited data were available to understand
- 82 the risk of breakthrough infections (a COVID-19 case despite being fully vaccinated) in people
- 83 with high-risk medical conditions in the U.S. Prior studies in unvaccinated populations have
- 84 shown more severe outcomes for COVID-19 infection for people with certain high-risk
- 85 comorbidities such as diabetes, chronic kidney disease (CKD), or who are
- 86 immunocompromised, e.g., because of cancer, solid organ transplant, or HIV (5–8).
- 87 Before the SARS-CoV-2 delta variant became prevalent, one study of 108,720 mostly male U.S.
- veterans with high-risk conditions showed vaccine effectiveness for preventing infection
- remained high (>95%) but did not evaluate the risk of severe disease (9). Another study in a
- 90 similar population did not show an elevated risk of severe outcomes in breakthrough infections
- 91 (10). In order to better understand the risk of breakthrough infection and severe outcomes in
- 92 high-risk populations, we the newly developed Truveta Platform to ask whether vaccinated
- 93 patients with comorbidities have higher rates of breakthrough COVID-19 infection and higher
- 94 rates of hospitalization following breakthrough infection than in those vaccinated but without the
- 95 studied comorbidities.
- 96

97 Methods

- 98 Our study population included a subset of fully vaccinated patients present in the de-identified
- 99 Truveta electronic health records (EHR) Platform from January 1, 2019, to January 10, 2022
- 100 (11). This covers patients across Alaska, California, Montana, New Mexico, Oregon, Texas, and
- 101 Washington. A patient was considered fully vaccinated two weeks after receiving two mRNA
- 102 vaccine doses (Moderna or Pfizer) or two weeks after receiving a single dose of the Janssen
- 103 vaccine. Additionally, patients were excluded from our study population if they were missing sex
- 104 or age fields, experienced a COVID-19 infection prior to being fully vaccinated (i.e., 14 days

- 105 post last dose of primary series), had no health system encounters following vaccination, were
- 106 missing their date of being fully vaccinated, were under 12 years of age at time of vaccination,
- 107 or had any vaccination events prior to December 1st, 2020. These last three criteria likely
- 108 indicated a recording error in patient age at vaccination or their time of vaccination. All
- 109 vaccination events were extracted from the EHR from member health systems; these events
- 110 generally consisted of vaccinations that took place within the health system as well as
- 111 vaccination records actively pulled from the health system's respective state's Immunization
- 112 Information System.
- 113 Comorbidities were defined using Elixhauser comorbidity ICD-10-CM diagnostic codes taken
- 114 from the patient's medical record (12), and included chronic kidney disease (CKD), chronic lung
- 115 disease/chronic obstructive pulmonary disease (COPD), diabetes, and those in an
- 116 immunocompromised state. CKD was defined as the earliest date a patient had an ICD-10-CM
- 117 diagnostic code consistent with CKD or when Kidney Disease: Improving Global Outcomes
- 118 (KDIGO) criteria for CKD were met by estimated glomerular filtration rate (eGFR) criteria (13).
- 119 For each comorbidity of interest, patients with that comorbidity diagnosed prior to being fully
- 120 vaccinated were compared with patients with none of the comorbidities of interest. Patients who
- 121 were diagnosed with a comorbidity after being fully vaccinated were excluded from analysis to
- 122 ensure the risk of breakthrough infection after vaccination was associated with a comorbidity
- 123 extant before vaccination. The complete list of comorbidity ICD-10 codes is presented in the
- 124 Supplementary Material.
- 125 Our response variables of interest were 1) if a patient experienced a breakthrough COVID-19
- 126 infection at any point after being fully vaccinated, and 2) if a patient who experienced a
- 127 breakthrough infection was hospitalized. SARS-CoV-2 infection was defined as a patient's first
- 128 diagnosis of COVID-19 as per ICD-10-CM code (U07.1). COVID-19 hospitalizations were
- 129 defined as an inpatient encounter where the patient's SARS-CoV-2 positivity fell within the
- 130 interval of 14 days prior to admission up to the date of discharge.
- 131 To account for potential confounding, we used inverse probability weighting (IPW) for each of
- the comorbidities with the following confounding features as predictors: age (<18, 18-49, 50-64,
- 133 65-74, 75+), race (White, Asian, Black or African American, American Indian or Alaska Native,
- 134 Native Hawaiian or Other Pacific Islander, Unknown), ethnicity (Hispanic or Latino, Not Hispanic
- 135 or Latino, and Unknown), and sex. Propensity scores were estimated using logistic regression
- and transformed into IPWs to estimate the average effect of the comorbidity on those patients'
- 137 outcomes (i.e., average "treatment" effect in the "treated") (14). IPWs were calculated

separately for the breakthrough infection analysis and the hospitalization following breakthroughinfection analysis.

- 140 Event rates were calculated using the weighted data. The proportion of breakthrough cases was
- 141 calculated as the number of patients with a given comorbidity who experienced a breakthrough
- 142 COVID-19 infection divided by the total number of patients with that comorbidity to yield a rate,
- 143 weighted by the IPWs. The confidence interval for this proportion was calculated using the
- 144 normal approximation of the binomial confidence interval (15). See Supplemental Code at
- 145 <u>https://github.com/Truveta/smits_et_al_covid_breakthrough_comorbidities</u>.
- 146 The weighted event rates for the population of patients without any of the comorbidities were
- 147 different for each of the focal comorbidities because of how each population was weighted to
- 148 resemble their respective group of patients with the comorbidity. To ease visual comparison, we
- calculated a composite of these four weighted event rates using a Binomial Generalized Linear
- 150 Model with only an intercept to estimate an average event rate from these samples. This
- 151 composite was not used in any statistical comparisons and was only used to ease absolute
- 152 interpretation of outcomes (e.g., Figure 1). This process was repeated for patients who
- 153 experienced hospitalization post breakthrough COVID-19.
- 154 Odds ratios (ORs) of breakthrough infection associated with a comorbidity were calculated
- 155 using logistic regression weighted using the calculated IPWs. This method was repeated for
- 156 calculating the OR of hospitalization following breakthrough infection associated with a
- 157 comorbidity. The confounding demographic features used in the weighting model were included
- as additional covariates in these regression models. ORs were calculated as the exponentiated
- regression coefficient (16) for the comorbidity covariate in the logistic regression model. Each
- 160 comorbidity was analyzed independently. This process was repeated for the analysis of
- 161 hospitalization following breakthrough infection.
- 162 Analysis was done using the R programming language (4.1.1)(17) along with the following
- packages: arrow(18), broom(19), dplyr(20), ggplot2(21), janitor(22), magrittr(23), purrr(24),
- 164 questionr(25), rlang(26), stringr(27), tableone(28), targets(29), tibble(30), and tidyr(31).
- 165

166 Results

167 Study population

	Sample Size	Change in Sample Size
Raw Sample Size	3424965	

	Sample Size	Change in Sample Size
No Missing Sex and Vaccination Date	3130114	294851
No Previous COVID-19 Infection	3059106	71008

168

No Encounters After Vaccination	2262391	796715
No Impossible Times	2109302	153089
No Missing Ages or Ages <= 12 years	2106893	2409
Final Sample Size	2106893	0

169 **Table 1**: Study population sample size. Table shows the determination of final sample sized

170 used in the analysis.

171

172 Our overall study population included 3,424,965 fully vaccinated patients. 1,318,072 patients

were excluded based on inclusion criteria, resulting in 2,106,893 patients for analysis. We

174 assigned to each patient whether they have a specific comorbidity or are comorbidity-free. This

175 led to five populations, one for each comorbidity of interest and one comorbidity-free general

176 population. If a patient has multiple comorbidities, they were assigned to each of the

177 corresponding comorbidities sub populations, see also the limitations discussion below for

details. Table 1 summarizes the distributions of raw patient counts within each sub population.

	General Population (Comorbidity- free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompr omised
Overall					
N (fully vaccinated patients)	1,593,780 (100.00%)	109,513 (100.00%)	242,687 (100.00%)	158,284 (100.00%)	159,351 (100.00%)
Breakthrough Case	31,062 (1.95%)	3,055 (2.79%)	6,386 (2.63%)	3,764 (2.38%)	2,922 (1.83%)
Hospitalized for Breakthrough Case	1,856 (0.12%)	806 (0.74%)	653 (0.27%)	633 (0.40%)	466 (0.29%)
Age Group					

	General Population (Comorbidity- free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompr omised
<18	72,080 (4.52%)	115 (0.11%)	8,347 (3.44%)	462 (0.29%)	351 (0.22%)
18-49	676,410 (42.44%)	5,748 (5.25%)	72,302 (29.79%)	21,955 (13.87%)	18,960 (11.90%)
50-64	419,257 (26.31%)	18,511 (16.90%)	66,124 (27.25%)	49,188 (31.08%)	42,357 (26.58%)
65-74	262,984 (16.50%)	33,109 (30.23%)	53,051 (21.86%)	47,866 (30.24%)	50,458 (31.66%)
75+	163,049 (10.23%)	52,030 (47.51%)	42,863 (17.66%)	38,813 (24.52%)	47,225 (29.64%)
Sex					
Female	970,513 (60.89%)	58,487 (53.41%)	155,099 (63.91%)	80,571 (50.90%)	93,785 (58.85%)
Male	622,626 (39.07%)	51,004 (46.57%)	87,514 (36.06%)	77,655 (49.06%)	65,531 (41.12%)
Other	641 (0.04%)	22 (0.02%)	74 (0.03%)	58 (0.04%)	35 (0.02%)
Race					
White	1,046,279 (65.65%)	82,647 (75.47%)	187,443 (77.24%)	107,640 (68.00%)	132,706 (83.28%)
Asian	153,193 (9.61%)	7,637 (6.97%)	15,008 (6.18%)	16,269 (10.28%)	8,417 (5.28%)
Black or African American	39,430 (2.47%)	5,706 (5.21%)	9,095 (3.75%)	7,901 (4.99%)	3,826 (2.40%)
American Indian or Alaska Native	10,399 (0.65%)	877 (0.80%)	2,903 (1.20%)	2,129 (1.35%)	1,096 (0.69%)
Native Hawaiian or Other Pacific Islander	6,867 (0.43%)	799 (0.73%)	1,579 (0.65%)	1,574 (0.99%)	569 (0.36%)
Other	337,612 (21.18%)	11,847 (10.82%)	26,659 (10.98%)	22,771 (14.39%)	12,737 (7.99%)
Ethnicity					
Hispanic or Latino	212,628 (13.34%)	9,798 (8.95%)	20,546 (8.47%)	18,711 (11.82%)	8,067 (5.06%)
Not Hispanic or Latino	1,201,147 (75.36%)	95,615 (87.31%)	213,497 (87.97%)	133,524 (84.36%)	145,900 (91.56%)
Other	180,005	4,100 (3.74%)	8,644 (3.56%)	6,049 (3.82%)	5,384 (3.38%)

General Population (Comorbidity- free)	Chronic Kidney Disease	Chronic Lung Disease	Diabetes	Immunocompr omised
(11.29%)				

Table 2: Baseline characteristics table for each comorbidity population along with the reference

181 comorbidity-free general population. If a patient has multiple comorbidities, they were assigned

to multiple corresponding comorbidity sub populations. Data represented are unweighted counts

- 183 of patients.
- 184
- 185 Percentage of vaccinated with breakthrough case
- 186 Figure 1 and Table 3 summarize the association between comorbidities and the likelihood of

187 having a COVID-19 breakthrough infection. Figure 1 shows the percentage of the population

- 188 that experienced a breakthrough infection and the ORs of breakthrough infections for individuals
- 189 with comorbidities compared to a comorbidity-free population, both calculated from weighted
- 190 data. Table 2 includes the results for each individual population as well as the computed
- 191 average comorbidity-free general population. In general, we see that those with chronic lung
- disease are more likely to have a breakthrough infection (2.63% [95% Confidence Interval:
- 193 2.57% 2.70%], OR: 1.43 [95% CI:1.37 1.48]), followed by those with diabetes (2.38% [95%
- 194 Cl: 2.30% 2.45%], OR: 1.29 [95% Cl: 1.23 1.36]).





- 196 Figure 1: Left: Percentage of the analyzed vaccinated population that experienced a
- 197 breakthrough COVID-19 infection among individuals with comorbidities compared to a
- 198 comorbidity-free population. These values are estimated from the propensity score weighted
- data. Right: ORs for breakthrough infection associated with having a comorbidity versus having
- 200 none of the analyzed comorbidities.
- 201

Percentage of vaccinated with breakthrough case (95% CI)					
	Comorbidity Population	General Population	OR		
Chronic Kidney Disease	2.30% (2.20% - 2.41%)	1.73% (1.64% - 1.82%)	1.34 (1.24 - 1.43)		
Chronic Lung Disease	2.63% (2.57% - 2.70%)	1.86% (1.81% - 1.91%)	1.43 (1.37 - 1.48)		
Diabetes	2.38% (2.30% - 2.45%)	1.85% (1.78% - 1.92%)	1.29 (1.23 - 1.36)		
Immunocompromised	1.83% (1.77% - 1.90%)	1.72% (1.65% - 1.78%)	1.07 (1.01 - 1.13)		
General Population		1.77% (1.74% - 1.81%)			

Table 3: Underlying data table that is used to generate Figure 1. Each cell contains the

203 estimated value as well as its 95% confidence interval (CI). The average comorbidity-free

204 general population was computed to simplify the visual representation within the left side of

205 Figure 1.

206

207 Percentage of breakthrough cases who are hospitalized

Figure 2 and Table 3 summarize our results based on the weighted population or risk of

209 hospitalization from breakthrough infection. In contrast to infection risk, those with CKD were

210 more likely to be hospitalized from breakthrough infection (26.43% [95% Confidence Interval:

211 24.43% - 28.54%], OR: 2.22 [95% CI: 1.88 – 2.63]). Differently, those with diabetes and those

- immunocompromised patients were the other highest risk groups with 16.82% (95% CI: 15.64%
- 213 18.06%) and 15.95% (95% CI: 14.65% 17.34%) hospitalized, respectively, and ORs of 1.81

214 (95%CI: 1.58 – 2.08), and 1.52 (95%CI: 1.31 – 1.77), respectively.



- 216 Figure 2: Left: Percentage of population that experienced hospitalization following a
- 217 breakthrough COVID-19 infection among individuals with comorbidities compared to a
- 218 comorbidity-free general population. These values are estimated from weighted data. Right:
- 219 ORs for hospitalization following a breakthrough infection associated with having a comorbidity
- 220 versus having none of the analyzed comorbidities.
- 221

Percentage of breakthrough cases who are hospitalized (95% CI)					
	Comorbidity Population	General Population	OR		
Chronic Kidney Disease	26.43% (24.43% - 28.54%)	- 13.91% (12.37%) 15.61%)	2.22 (1.88 - 2.63)		
Chronic Lung Disease	10.23% (9.50% - 11.00%)	7.67% (7.03% - 8.35%)	1.37 (1.21 - 1.55)		
Diabetes	16.82% (15.64% - 18.06%)	10.05% (9.11% - 11.06%)	1.81 (1.58 - 2.08)		
Immunocompromised	15.95% (14.65% - 17.34%)	11.10% (9.99% - 12.30%)	1.52 (1.31 - 1.77)		
General Population		8.85% (8.42% - 9.29%)			

- Table 4: Each cell contains the estimated value as well as its 95% confidence interval (CI). The
- 223 average comorbidity-free general population was computed to simplify the visual representation
- within the left side of Figure 2.
- 225
- 226 Discussion

Here we found that the incidence of SARS-CoV-2 breakthrough infection and COVID-19

- 228 hospitalization following breakthrough infection were significantly greater among patients with
- select comorbid medical conditions when compared to the general population. Specifically,
- 230 people with diabetes, chronic lung disease, or CKD have increased incidence of breakthrough
- infection compared to the general population after adjusting for age, sex, race, and ethnicity.
- These conditions are thought to lead to impaired immune function (32–34). This is consistent
- 233 with studies in unvaccinated people showing higher risk of infection in these populations as well
- as a study in mostly male U.S. veterans which showed reduced vaccine effectiveness in
- 235 patients with a high Charlson comorbidity index (9).
- In our study, patients with comorbidities had nearly twice the odds of being hospitalized than the
- 237 general vaccinated population. Overall, these findings add to prior studies showing worse
- 238 outcomes following COVID-19 infection in people who are immunocompromised, with diabetes,
- 239 CKD, or with chronic lung disease (5–7) and adds additional support for recommendations of
- 240 booster vaccines given these groups continue to fare worse than the general vaccinated
- 241 population. One study in an unvaccinated population reported ORs of greater than 2 for in-
- 242 hospital mortality following COVID-19 infection in patients with diabetes, CKD, or pulmonary
- 243 disease when compared with the general population (6). We identified CKD as the highest risk
- 244 comorbidity for hospitalization, even after adjustment for age and demographic factors. Notably,
- a large study in male U.S. veterans did not show an elevated risk of severe outcomes in
- breakthrough infections in patients with diabetes, chronic lung disease, or CKD (10). This was
- 247 possibly due to their study design which matched patients by comorbidity burden thereby
- reducing any differences between groups. In contrast our study compared patients with
- 249 identified comorbidities to a control group without these comorbidities and did not exclude or
- 250 match patients with multiple comorbidities.
- 251 We found that the immunocompromised group had the smallest increased risk of breakthrough 252 infection compared to the other comorbidities. This is possibly due to a higher adoption of 253 protective behaviors such as social distancing and mask wearing in this group than other groups 254 and the general population. Additionally, while we found that those with chronic lung disease 255 had the highest rate of breakthrough infection (2.63%) it had the lowest rate of hospitalization 256 (10.23%). This might be due to those with COPD having supplemental oxygen and steroids 257 readily available, or that COPD may capture a broad range of disease from very mild asthma to 258 end-stage COPD, therefore attenuating overall risk of hospitalization in our data; though future 259 research is necessary.

Like all studies, ours is subject to limitations. First, there are multiple confounding features

- which are difficult to address with the available data including the timing of patient vaccination,
- 262 precedent undiagnosed COVID-19 infection, and the timing of infections in relation to SARS-
- 263 CoV-2 variants of concern. Future studies should correct for these potential confounders.
- 264 Secondly, our current data definitions rely heavily on ICD-10-CM codes, except for CKD which
- 265 incorporates lab tests. This limits the scope and may limit the accuracy of our comorbidity
- 266 groups and COVID-19 diagnoses. For example, adding labs would improve sensitivity for
- 267 COVID-19 cases. As more data become available, we plan to include SARS-CoV-2 variants of
- 268 concern, geography, and more comorbidities.
- 269 Our current outcome models consider only the effect of a single comorbidity on our outcomes of
- 270 interest. Future iterations of this analysis should consider the effect of multiple simultaneous
- 271 comorbidities on outcomes as well as their interaction effects. Currently, we treat each
- 272 comorbidity as purely independent, but it is known that patients can have multiple comorbidities
- 273 (e.g., diabetes and CKD). Future research could consider the interaction effects of patients
- 274 having multiple comorbidities on probabilities of outcome events; specifically, models of
- 275 breakthrough infection and hospitalization outcomes should consider how the interactions
- among these comorbidities may contribute to differences in odds of breakthrough infection and
- 277 hospitalization.

278 As vaccinated individuals continue to make decisions about booster vaccinations, they will be 279 looking for information regarding their personal risk of breakthrough COVID-19 infection and 280 severe outcomes like hospitalization. The FDA and CDC both made recommendations to 281 include high-risk groups, such as those we studied, as groups who should receive booster 282 vaccinations. While there is robust data showing increased risk to unvaccinated groups with 283 comorbidities, both the FDA and CDC cited limited data in vaccinated groups with comorbidities. 284 The findings of this study improve the evidence and support recommendations for people with 285 comorbidities such as chronic kidney disease, chronic lung disease, diabetes or people who are 286 immunocompromised to receive the primary vaccination sequence as well as a booster dose.

- 287
- 288

289 References

- Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, et al. Comparison of two highlyeffective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence [Internet]. Public and Global Health; 2021 Aug [cited 2021 Oct 27]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.08.06.21261707
- Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, et al. Resurgence of SARS-CoV-2
 Infection in a Highly Vaccinated Health System Workforce. N Engl J Med. 2021 Sep 30;385(14):1330–2.
- Oliver, Sara. ACIP Presentation Slides: Sept 22-23, 2021, Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 Booster Dose. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-9-23/03-COVID-Oliver.pdf
- Dooling K. ACIP Presentation Slides: Oct 21, 2021, Evidence to Recommendation Framework: Moderna & Janssen COVID-19 Vaccine Booster Dose. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/11-COVID-Dooling-508.pdf
- Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz B, Zink RC, et al. Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. Clin Infect Dis. 2021 May 18;72(10):e558–65.
- Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. Verdonck K, editor. PLOS ONE. 2020 Nov 3;15(11):e0241742.
- Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect. 2020 Aug;81(2):e93–5.
- Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020 Nov;139:43–50.
- Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting. Ann Intern Med. 2021 Oct;174(10):1404–8.
- Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. EClinicalMedicine. 2021 Oct;40:101117.
- 319 11. Truveta. Truveta Platform. [cited 2021 Oct 27]; Available from: http://truveta.com
- 320
 12. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity Measures for Use with Administrative Data: Med Care. 1998 Jan;36(1):8–27.
- 322
 13. Chapter 1: Definition and classification of CKD. KDIGO 2012 Clin Pract Guidel Eval Manag Chronic Kidney Dis. 2013 Jan 1;3(1):19–62.
- Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in
 Observational Studies. Multivar Behav Res. 2011 May 31;46(3):399–424.
- Agresti A. Categorical data analysis. 3rd ed. Hoboken, NJ: Wiley; 2013. 714 p. (Wiley series in probability and statistics).
- 328
 329
 16. Gelman A, Hill J, Vehtari A. Regression and other stories. Cambridge, United Kingdom: Cambridge University Press; 2021. 534 p. (Analytical methods for social research).
- R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R
 Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/

- Richardson N, Cook I, Crane N, Keane J, François R, Ooms J, et al. arrow: Integration to "Apache" "Arrow" [Internet]. 2021. Available from: https://CRAN.R-project.org/package=arrow
- Robinson D, Hayes A, Couch S. broom: Convert Statistical Objects into Tidy Tibbles [Internet]. 2021. Available from: https://CRAN.R-project.org/package=broom
- Wickham H, François R, Henry L, Müller K. dplyr: A Grammar of Data Manipulation [Internet]. 2021. Available from: https://CRAN.R-project.org/package=dplyr
- 338
 339
 21. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New York; 2016. Available from: https://ggplot2.tidyverse.org
- 340
 341
 22. Firke S. janitor: Simple Tools for Examining and Cleaning Dirty Data [Internet]. 2021. Available from: https://CRAN.R-project.org/package=janitor
- 342
 343
 23. Bache SM, Wickham H. magrittr: A Forward-Pipe Operator for R [Internet]. 2020. Available from: https://CRAN.R-project.org/package=magrittr
- Henry L, Wickham H. purrr: Functional Programming Tools [Internet]. 2020. Available from: https://CRAN.R-project.org/package=purrr
- Barnier J, Briatte F, Larmarange J. questionr: Functions to Make Surveys Processing Easier [Internet]. 2021.
 Available from: https://CRAN.R-project.org/package=questionr
- 348
 349
 26. Henry L, Wickham H. rlang: Functions for Base Types and Core R and "Tidyverse" Features [Internet]. 2021. Available from: https://CRAN.R-project.org/package=rlang
- Wickham H. stringr: Simple, Consistent Wrappers for Common String Operations [Internet]. 2019. Available from: https://CRAN.R-project.org/package=stringr
- 352
 28. Yoshida K, Bartel A. tableone: Create "Table 1" to Describe Baseline Characteristics with or without Propensity Score Weights [Internet]. 2021. Available from: https://CRAN.R-project.org/package=tableone
- 29. Landau W. The targets R package: a dynamic Make-like function-oriented pipeline toolkit for reproducibility and high-performance computing. J Open Source Softw. 2021 Jan 15;6(57):2959.
- 356
 30. Müller K, Wickham H. tibble: Simple Data Frames [Internet]. 2021. Available from: https://CRAN.R-project.org/package=tibble
- 358 31. Wickham H. tidyr: Tidy Messy Data [Internet]. 2021. Available from: https://CRAN.R-project.org/package=tidyr
- 359 32. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab. 1992 Jun;18(3):187–201.
- 362
 33. O'Dwyer DN, Dickson RP, Moore BB. The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease. J Immunol. 2016 Jun 15;196(12):4839–47.
- 364 34. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of Uremia on Structure and Function of Immune System. J Ren Nutr. 2012 Jan;22(1):149–56.